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ABSTRACT
Introduction Cardiovascular disease is the leading 
cause of morbidity and mortality in patients with 
type 2 diabetes (T2D). Although glycaemic control 
reduces microvascular complications, the effect of 
intensive treatment strategies or individual drugs on 
macrovascular diseases is still debated. RNA oxidation 
is associated with  increased mortality in patients with 
T2D. Inspired by animal studies showing effect of a 
sodium-glucose cotransporter-2 (SGLT-2) inhibitor 
(empagliflozin) on oxidative stress and a recent trial 
evaluating empagliflozin that demonstrated improved 
cardiovascular outcomes in patients with T2D at high 
risk of cardiovascular events, we hypothesise that 
empagliflozin lowers oxidative  stress.
Methods and analysis In this randomised, double-
blinded and placebo-controlled study, 34 adult males 
with T2D will be randomised (1:1) to empagliflozin or 
placebo once daily for 14 days as add-on to ongoing 
therapy. The primary endpoints will be changes in 24-
hour urinary excretion of 8-oxo-7,8-dihydroguanosine 
(8-oxoGuo) and 8-oxo-7,8-dihydro-2’-deoxyguanosine 
(8-oxodG) determined before and after intervention 
(by ultra-performance liquid chromatography tandem 
mass-spectrometry). Additionally, fasting levels of 
malondialdehyde (MDA) will be determined in plasma 
before and after intervention (by high-performance 
liquid chromatography). Further, the plasma levels of 
iron, transferrin, transferrin-saturation, and ferritin are 
determined to correlate the iron metabolism to the 
markers of oxidative modifications.
Ethics and dissemination The study protocol has been 
approved by the Regional Committee on Biomedical 
Research Ethics (approval number H-16017433), the 
Danish Medicines Agency, and the Danish Data Protection 
Agency, and will be carried out under the surveillance 
and guidance of the GCP unit at Bispebjerg Frederiksberg 
Hospital, University of Copenhagen in compliance with the 
ICH-GCP guidelines and in accordance with the Declaration 
of Helsinki. The results of this study will be presented at 
national and international conferences, and submitted to 
a peer-reviewed international journal with authorship in 
accordance with Internation Committee of Medical Journal 
Editors (ICMJE) Recommendations state.
Trial registration Study name: EMPOX; Pre-results:  
clinicaltrials. gov (NCT02890745). Protocol version 5.1 - 
August, 2016.
INTRODUCTION
Diabetes is an increasing health issue 
affecting around 422 million people in the 
world, a doubling in prevalence since 1980.1 
More than 90% have type 2 diabetes (T2D). 
Patients with T2D have increased risk of 
developing cardiovascular diseases.2
The treatment target and strategy of T2D 
are individualised based on disease complica-
tions and comorbidity, with glycaemic control 
as the major focus.3 Although glycaemic 
control reduces the risk of microvascular 
complications,4 the effect of intensive treat-
ment strategies or individual drugs on 
macrovascular diseases is still debated.5–10
T2D is in general characterised as a meta-
bolic disease with insulin resistance and defect 
insulin production.11 Additionally, increased 
oxidative nucleic acid modifications have been 
observed.12–14 Of particular importance, RNA 
oxidation measured by urinary excretion of 
8-oxo-7,8-dihydriguanosiene (8-oxoGuo) has 
Strengths and limitations of this study
 ► This study will investigate the effect of empagliflozin 
on urinary excretion of 8-oxoGuo, since 8-oxoGuo 
is a prognostic biomarker for mortality in patients 
with type 2 diabetes (T2D).
 ► The trial design will be randomised, double blinded 
and placebo controlled.
 ► The methods for analysis of the outcomes are 
precise and reliable.
 ► A limitation is that the study outcome is not mortality 
in a long-term follow-up, but a biomarker prognostic 
for mortality in patients with T2D.
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been shown to be associated with increased mortality in 
both newly diagnosed patients with T2D13 and in patients 
with a 6-year disease duration of T2D.14 However, still 
no drug treatments have been demonstrated to reduce 
urinary excretion of 8-oxoGuo.15–18
Empagliflozin is a selective sodium/glucose cotrans-
porter 2 (SGLT-2)-inhibitor that increases urinary 
excretion of glucose, and thereby improves glycaemia in 
patients with T2D.19 Recently, the cardiovascular outcome 
trial EMPA-REG-OUTCOME study demonstrated that 
empagliflozin added to standard care in doses of 10 or 
25 mg once daily compared with placebo treatment 
reduces all-cause mortality and death from cardiovascular 
causes in patients with T2D and high-risk of cardiovascular 
disease.20 The effect of empagliflozin occurred fast, only 
3 months after treatment initiation.21 The mode of action 
behind these effects of empagliflozin remains debated. 
Additional effects to empagliflozin treatment such as 
lowering blood pressure and increased diuresis have been 
suggested, but not confirmed as explanatory.22 23
Empagliflozin reduces multiple markers of oxida-
tive modifications in rat models of type 1 diabetes.24 25 
In addition, it has been reported that empagliflozin 
lowers 8-iso prostaglandin f2α (8-iso-PGF2α) (a marker 
of lipid peroxidation) in patients with T2D. However, 
the methodologyfor determining 8-iso-PGF2α, was not 
reported.26
Several biomarkers of oxidative modifications are 
proven potential clinical relevant for different diseases.27 
Studies have demonstrated inconsistency between markers 
of oxidative modifications in different cellular compart-
ments.13 14 28 Hereby, this study differentiates the effect of 
empagliflozin on three different cellular compartments.
Iron contributes to increased levels of oxidative modi-
fications, and iron is hypothesised to be associated with 
development of diabetes.29 This study evaluates the 
correlation of iron, transferrin, transferrin saturation 
and ferritin with the markers of oxidative modifications.
Hypothesis and aims
We hypothesise that empagliflozin lowers oxidative 
nucleic acid modifications, measurable by urinary 
excretion of 8-oxoGuo and 8-oxo-7,8-dihydro-2’-deox-
yguanosine (8-oxodG). Further, we evaluate if there is 
a compartmentalisation of oxidative modifications in 
the organism and within the cell by also measuring the 
effect of empagliflozin on lipid peroxidation by plasma 
levels of malondialdehyde (MDA).
In addition to our primary hypothesis, this study inves-
tigates whether iron, transferrin, transferrin saturation, 
and ferritin are correlated to the levels of oxidative 
modifications (8-oxoGuo, 8-oxodG, and MDA) in 
patients with T2D.
Study objectives
The primary objectives are 24-hour urinary excretion of 
8-oxoGuo and 8-oxodG before and after treatment with 
empagliflozin compared with placebo as a measurement 
of whole-body RNA oxidation and DNA oxidation, respec-
tively.30
The secondary objectives encompass the concentra-
tion of MDA in plasma before and after treatment with 
empagliflozin compared with placebo treatment as a 
measurement of lipid peroxidation.31
Further, this study determines the concentration of 
iron, transferrin, transferrin saturation, and ferritin 
before and after the intervention to confirm and further 
explore the association between the iron metabolism and 
oxidative modifications.
METHODS AND ANALYSIS
The protocol is developed in accordance with the 
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) recommendation.32 33 The SPIRIT 
2013 Checklist for this protocol is available as "supple-
mentary data".
The trial is registered at http:// clinicaltrials. gov (pre-re-
sults: NCT02890745). Important changes in the protocol 
will be registered at the website, and addressed to the 
Danish Medicines Agency and the Regional Committee 
on Biomedical Research Ethics.
Trial design and setting
The trial will be randomised, placebo controlled, and 
double blinded with two parallel groups.
Participants will be recruited from the diabetes outpa-
tient clinic, Department of Medicine, Gentofte Hospital, 
University of Copenhagen, Hellerup, Denmark in relation 
to outpatient consultations. The recruitment continues 
until 34 participants have completed the trial successfully.
Eligibility of participants
Inclusion criteria
Male diagnosed with T2D
 ► Age: 18–75 years
 ► HbA1c: 6.5%–9.0%
 ► Capable of understanding oral and written 
information
 ► Caucasian
Exclusion criteria
 ► Estimated glomerular filtration rate (eGFR) <60 mL/
hour/1.73 m2
 ► Currently receiving insulin treatment
 ► Coronary artery bypass grafting, percutaneous 
coronary intervention, acute coronary syndrome, 
stroke, lung embolism, deep vein thrombosis or 
transitory cerebral ischaemia within 6 months
 ► Genital infection within 14 days
 ► Plasma alanine aminotransferase ≥3 times upper 
normal limit
 ► Treatment with SGLT-2 inhibitor within 2 months
 ► Hyperglycaemic symptoms
 ► Psychiatric disorder
 ► Intolerance to empagliflozin or other agents relevant 
to study
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 ► Non-compliant
Intervention
Participants will be randomised to receive once-daily 
empagliflozin 25 mg or placebo (in the morning) for 
2 weeks as add-on to ongoing therapy. Empagliflozin and 
placebo will be manufactured and labelled by Boehringer 
Ingelheim. The dosage of empagliflozin is standard 
medical treatment of T2D.34 Possible administration of 
sulfonylurea drugs to participants will be paused 1 week 
before the start visit and during the intervention to avoid 
hypoglycaemia during the trial. Otherwise, there will be 
no restriction to concomitant treatment. Participants 
will be encouraged not to change their lifestyle (i.e. diet, 
exercise and smoking status) during the trial.
Trial medicines comply with Good Manufacturing 
Practice regulations.35 Participants receive text message 
reminders of medicine intake during the intervention 
period.
Participants will be evaluated compliant to medicine 
intake at an adherence level of at least 65%.
Outcomes
Primary outcome measurements
The primary outcome of the trial will be the difference 
between 24-hour urinary excretion of 8-oxoGuo and 
8-oxodG before and after the intervention, which will be 
compared between the two treatment groups.
Secondary outcome measurements
The secondary outcome will be the difference between 
MDA in plasma before and after the intervention, which 
will be compared between the two groups. Further, this 
study correlates the concentration of iron, transferrin, 
transferrin saturation, and ferritin with the urinary excre-
tion of 8-oxoGuo and 8-oxodG.
Participant timeline
Participant timeline is illustrated in figure 1. Potential 
participants will be informed about the trial in relation 
to their outpatient consultation at the hospital. If they 
are interested in participating, a screening visit will be 
conducted after informed consent. At the screening 
visit, eligibility will be investigated. Blood pressure, pulse, 
height, and weight will be measured.
Participants will be fasting at the randomisation and 
end-of-study visit. At the randomisation visit, trial medi-
cine will be dispensed to participants, and 24-hour urine 
sample and a venous blood sample will be collected. 
After a 14-day treatment schedule, the end-of-study 
visit will take place. Participants will deliver the 24-hour 
urine sample and excess trial medicine, and a venous 
blood sample will be collected. All adverse events will 
be registered.
The 24-hour urine sample will be collected from the 
morning of the day before the visit to the morning of the 
day of the visit. The participant will empty his bladder 
in the morning before the collection of 24-hour urine 
begins.
The first participant’s screening visit is expected to be 
on 25 October 2016. The last participant’s end-of-study 
visit is expected to be on  31 July 2017.
Sample size
An a priori power calculation has been performed with 
type I error risk of 5% and type II error risk of 20%. 
Values of the primary outcomes are about 30 nmol with 
SD of 6 nmol per 24 hour based on baseline values from 
the PENTRIOX trial.36 Smoking increases urinary excre-
tion of 8-oxodG by 50% (95% CI 31% to 69%).37 We wish 
to be able to detect an effect size of 20%, since we do not 
believe smaller changes are clinically relevant. The type 1 
and type 2 errors are set at conventional values.
The power calculation based on these assumptions esti-
mated 17 participants in each group using SAS version 
9.4 (SAS Institute, Inc., Cary, NC, USA).
Assignment of intervention
The randomisation will be carried out through a simple 
randomisation with a 1:1 allocation ratio from a comput-
er-generated list of random numbers.
The list of random numbers will be made by an 
employee who otherwise will be uninvolved in the study. 
Figure 1 Participant timeline.
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The allocation sequence will be concealed from the 
investigators and healthcare staff enrolling and assessing 
participants.
The physicians responsible for the treatment of patients 
with T2D in the outpatient clinic will inform potential 
participants about the trial and will offer them an infor-
mation meeting. At the information meeting, ELL, LKK, 
and/or VC will inform potential participants about the 
trial, and the potential participants will receive written 
information as well. The screening visit will be performed 
by ELL, LKK, and/or VC after written informed consent 
is obtained. ELL, JR, TV, and FKK will be responsible for 
the enrolment of participants and assignment of inter-
vention. The end-of-study visit will be performed by ELL, 
LKK, and/or VC. HEP is the sponsor-investigator of the 
study. JR is the principal investigator of the study.
Only HEP, ELL, LKK, and VC will have access to the 
final dataset until after analysis of the data. After anal-
ysis and code break of the trial all investigators have full 
access to the dataset.
Participants, research coordinator, investigators and labo-
ratory technicians will be blinded until data are analysed.
Code break of a participant’s trial medicine will occur 
only under exceptional circumstances when knowledge 
of treatment is absolutely necessary. Only the principal 
investigator and an employee who is otherwise unin-
volved in the study will be able to perform a code break. 
Since they will not be part of the data analysis, a potential 
code break will not be of critical importance.
Data collection, analysis and management
Urine and plasma samples will be collected at the rando-
misation visit and the end-of-study visit. In order to 
improve adherence of the 24-hour urine sample, partic-
ipants will receive three text message reminders of the 
sample collection during the sample collection period. If 
participants record loss of a urine void, 150 mL will be 
added to the recorded diuresis. Participants will be evalu-
ated for their compliance to 24-hour urinary collection at 
an adherence level of at least 75%.
Urine samples will be stored at −20°C until data anal-
ysis. The samples will be analysed after last participant’s 
end-of-study visit by ultra-performance liquid chroma-
tography tandem mass spectrometry (UPLC-MS/MS). 
The frozen urine samples will be heated to 37°C and 
centrifuged at 10 000 g for 5 min prior to addition of 
lithium acetate and internal standard. The chromato-
graphic separation will be performed by an Acquity 
UPLC I-class system with an Acquity UPLC BEH Shield 
RP18 column (1.7 µm, 2.1×100 mm) (Waters, Milford, 
Massachusetts, USA) with mobile phases A: 5 mM ammo-
nium acetate and B: acetonitrile. The mass spectrometric 
detection will be performed by a Xevo TQ-S triple quadru-
lope mass spectrometer (Waters, Milford, Massachusetts, 
USA) with Intellistart function (MassLynx V.4.1).18 
Further details of the method and quality control are 
described elsewhere.18 Liquid chromatography tandem 
mass spectrometry (LC-MS/MS) is the preferred method 
to determine urinary excretion of 8-oxoGuo and 8-oxodG 
due to the high specificity.38
Plasma samples will be stored at −80°C until data anal-
ysis. The samples will be analysed after last participant’s 
end-of-study visit by high-performance liquid chromatog-
raphy (HPLC). Phosphotungstic acid will be added to the 
samples before centrifuged for 3 min at 16 000 g. Then 
butylated hydroxytoluene will be added to avoid further 
peroxidation. Thiobarbituric acid (TBA) reagent and 
acetic acid will be added and the mixture will be heated to 
95°C for 60 min to form MDA(TBA)2 adduct. MDA(TBA)2 
will be determined by HPLC with fluorescence detection 
(excitation, 515 nm; emission).31 Further details of the 
method and quality control are described elsewhere.31 
The HPLC method has a high specificity, thus preferred 
for determining MDA.39
The study will collect demographic and baseline infor-
mation from the participant’s physicians.
All data will be written in Case Report Form (CRF). 
CRFs will only be available for investigators and research 
coordinator, stored at trial site locked away according 
to ICH-GCP guidelines.40 The data will be entered into 
a locked database by double data entry after last partici-
pant’s end-of-study visit.
The trial will be monitored by the GCP unit, Bispeb-
jerg Hospital, University of Copenhagen, Copenhagen, 
Denmark. The GCP unit and the Danish Medicines 
Agency will be able to conduct an audit of the trial inde-
pendent of sponsor-investigator and investigators.
The treatment period will be short, and empagliflozin 
is in general well tolerated. Therefore, only few adverse 
reactions are to be expected. Participants will be informed 
of possible adverse reactions and told to contact an inves-
tigator if he experiences a possible adverse reaction. 
Adverse events will be registered at the end-of-study visit. 
All adverse events will be reported to the Danish Medi-
cines Agency and the Regional Committee on Biomedical 
Research Ethics at the end of trial.
Fatal or life-threatening Suspected Unexpected Serious 
Adverse Reactions (SUSARs) will be reported to Danish 
Medicines Agency and the Regional Committee on 
Biomedical Research Ethics within 7 days. Other SUSARs 
will be reported to Danish Medicines Agency and the 
Regional Committee on Biomedical Research Ethics 
within 15 days. The participants will be insured by the 
Capital Region of Denmark, Gentofte Hospital. Principal 
investigator will have the final decision on whether an 
adverse event requires additional treatment, exclusion 
from the trial, or termination the entire trial.
Statistical analysis
All analyses will be conducted per protocol. Any drop-out 
of the trial will be described in the results.
Baseline demographic and clinical characteristics will 
be compared using a Student’s t-test. If the two groups 
are not equal after randomisation in demographic or clin-
ical parameters then a logistic regression will be used to 
correlate the result for these parameters.
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The difference in primary and secondary outcomes 
before and after intervention will be compared between 
the groups using Student’s t-test.
Data will be evaluated for normal distribution using 
graphical illustration and the Shapiro-Wilk test, and further 
validated using a non-parametric test. If data are not 
normally distributed, data will be log-transformed before 
analyses or subjected to a non-parametric test for analysis.
A two-sided p<0.05 will be considered statistically signif-
icant.
Strengths and limitations
The study explores if empagliflozin influences oxida-
tion of nucleic acids as a prerequisite before conducting 
a controlled trial with oxidative stress and mortality as 
endpoints.The strength of this study is the randomised, 
placebo-controlled, double-blinded trial design. The 
biomarker 8-oxoGuo is prognostic for mortality in 
patients with T2D, and the methods for analysis of both 
primary and secondary outcomes are precise and reliable. 
A limitation is that the study outcome is not mortality with 
a long-term follow up, but a biomarker prognostic for 
mortality in patients with T2D.
ETHICS AND DISSEMINATION
The study has received approval from the Regional 
Committee on Biomedical Research Ethics (approval 
number H-16017433), the Danish Medicines Agency, 
and the Danish Data Protection Agency. The study is 
performed with informed consent from participants in 
agreement to the Declaration of Helsinki. Additional 
plasma samples will be stored at -80˚C for use in future 
research, locked away at the Department of Pharma-
cology, University Hospital Rigshospitalet. The results of 
the study will be presented at national and international 
conferences, and submitted at a peer-review international 
journal.
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